ASH 2022 | Approaches taken for patients with multiple myeloma with resistance to lenalidomide and bortezomib
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, outlines approaches and therapies available for patients with multiple myeloma who develop resistance to lenalidomide and bortezomib. In a double-refractory setting, Dr Ramasamy explains how pomalidomide or carfilzomib-based therapies are usually administrated. Additionally, a combination of anti-CD38 monoclonal antibodies and pomalidomide or carfilzomib is considered for CD38-naïve patients. Dr Ramasamy further emphasizes the importance of including these patients in ongoing clinical trials, particularly trials evaluating bispecific antibodies and BCMA-targeted agents. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda, Bristol Myers Squibb, Janssen, Amgen, GlaxoSmithKline: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Other: Travel, Research Funding, Speakers Bureau; Sanofi, Adaptive biotech, Oncopeptides: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau.
